115 related articles for article (PubMed ID: 38281899)
1. Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study.
Murata F; Maeda M; Ono R; Fukuda H
Vaccine; 2024 Feb; 42(6):1268-1274. PubMed ID: 38281899
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
3. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events.
Ihara H; Kikuchi K; Taniguchi H; Fujita S; Tsuruta Y; Kato M; Mitsuishi Y; Tajima K; Kodama Y; Takahashi F; Takahashi K; Azuma N
Vaccine; 2019 Oct; 37(43):6447-6453. PubMed ID: 31526624
[TBL] [Abstract][Full Text] [Related]
4. Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study.
Li CY; Chen LC; Lin HY; Lee MS; Hung SK; Lai CL; Huang LW; Yu BH; Hsu FC; Chiou WY
Cancer; 2021 Jan; 127(1):124-136. PubMed ID: 32997342
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine.
Hsiao A; Hansen J; Timbol J; Lewis N; Isturiz R; Alexander-Parrish R; McLaughlin JM; Gessner BD; Klein NP
JAMA Netw Open; 2022 Mar; 5(3):e221111. PubMed ID: 35302634
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.
Chiou WY; Lee MS; Hung SK; Lin HY; Lo YC; Hsu FC; Tsai SJ; Li CY
BMJ Open; 2018 May; 8(5):e019364. PubMed ID: 29769253
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly patients with colorectal cancer: A population-based propensity score-matched cohort study.
Chiou WY; Hung SK; Lin HY; Chen LC; Hsu FC; Tsai SJ; Yu BH; Lee MS; Li CY
Medicine (Baltimore); 2019 Dec; 98(50):e18380. PubMed ID: 31852152
[TBL] [Abstract][Full Text] [Related]
8. Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study.
Chiou WY; Hung SK; Lai CL; Lin HY; Su YC; Chen YC; Shen BJ; Chen LC; Tsai SJ; Lee MS; Li CY
Medicine (Baltimore); 2015 Jul; 94(26):e1022. PubMed ID: 26131806
[TBL] [Abstract][Full Text] [Related]
9. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children: a retrospective, population-based, record-linked cohort study.
Fathima P; Gidding HF; McIntyre PB; Snelling TL; McCallum L; de Klerk N; Blyth CC; Liu B; Moore HC
Lancet Child Adolesc Health; 2019 Oct; 3(10):713-724. PubMed ID: 31439496
[TBL] [Abstract][Full Text] [Related]
12. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
14. Effect of the 23-valent pneumococcal polysaccharide vaccine on the incidence of hospitalization with pneumonia in adults aged ≥65 years: retrospective cohort study using a population-based database in Japan.
Yamana H; Ono S; Michihata N; Uemura K; Jo T; Yasunaga H
Clin Microbiol Infect; 2023 Jul; 29(7):904-910. PubMed ID: 37044276
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study.
Heo JY; Seo YB; Choi WS; Kim EJ; Jeong HW; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Song JY
J Infect Dis; 2022 Mar; 225(5):836-845. PubMed ID: 34537847
[TBL] [Abstract][Full Text] [Related]
16. Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017-2018.
Vila-Córcoles A; Ochoa-Gondar O; de Diego-Cabanes C; Satué-Gracia EM; Torras-Vives V; Forcadell-Peris MJ; Ribas-Seguí D; Vila-Rovira A; Rodríguez-Casado C
Vaccine X; 2023 Apr; 13():100264. PubMed ID: 36798107
[TBL] [Abstract][Full Text] [Related]
17. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.
Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y
Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
20. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study.
Rodriguez-Barradas MC; Goulet J; Brown S; Goetz MB; Rimland D; Simberkoff MS; Crothers K; Justice AC
Clin Infect Dis; 2008 Apr; 46(7):1093-100. PubMed ID: 18444830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
